List view / Grid view
10 May 2016 | By Victoria White, Digital Content Producer
Scientists have designed a drug candidate, Targaprimir-96, that decreases the growth of tumour cells in animal models of triple negative breast cancer...
3 May 2016 | By Victoria White, Digital Content Producer
Scientists have shown how small structural changes in a key breast cancer receptor can produce predictable effects in curbing or accelerating cancer growth...
20 April 2016 | By Victoria White, Digital Content Producer
Emergent BioSolutions' ES425 molecule is being developed as a potential therapeutic for triple-negative breast cancer (TNBC)...
12 April 2016 | By Victoria White, Digital Content Producer
The discovery means that a family history of DCIS could be as important to assessing a woman’s risk as a history of invasive breast cancer...
7 March 2016 | By Victoria White
Scientists have provided a deeper insight into how BRCA1 functions in normal breast tissue and how its loss results in breast cancer...
9 February 2016 | By Victoria White
The programme aims to bring together breast cancer researchers and pharmaceutical companies to pool resources and stop women dying from breast cancer by 2050...
2 February 2016 | By Victoria White
A team of scientists from Bath, Cambridge and the USA has identified a piece of non-coding RNA that stops cells turning cancerous...
19 January 2016 | By Victoria White
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
8 January 2016 | By Victoria White
The first-in-class candidate, CB1, has shown potent anti-metastatic activity, and with an impressive in vivo efficacy and safety profile...
23 December 2015 | By Victoria White
A team at CSHL has announced preclinical data suggesting the promise of a novel drug directed against a novel target in malignant mammary tumours...
4 December 2015 | By Victoria White
ICR scientists have discovered Brf2 acts as a ‘master switch’ within cancer cells that seems to override the normal stress response...
2 December 2015 | By Victoria White
GBI Research states that the majority of oncology therapeutics are in the early stages of the pipeline, with 2,937 at the Preclinical stage and 1,591 at the discovery stage...
26 November 2015 | By Victoria White
Researchers from the University of Basel have, for the first time, successfully combined an antibody-drug conjugate with a therapy that stimulates the immune system to attack breast cancer cells...
23 November 2015 | By Victoria White
Evgen has said it will use its Sulforadex platform to synthesise and stabilise the newly acquired compounds with a view to taking the most promising into clinical development...
13 November 2015 | By Victoria White
The engineered cells induce apoptosis, where the cancer cells self-destruct and disintegrate, preventing the lymphatic spread of cancer any further...
